Tag Archive for: BRCA2
Phase 1 Trial of XL309: USP1 Inhibitor Targeting DNA Repair in Solid Tumors
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ASCO 2025 ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Follow-up of ARCHES Trial Shows Extended Survival September 4, 2025
- IND Required for ITC-6146RO for Solid Tumors Overexpressing the B7-H3 Protein September 2, 2025
- Anti-PD-L1 Therapy Shows Promise for MMR-Deficient Metastatic Prostate Cancer August 30, 2025
- Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN) August 29, 2025